Moderately interesting study with 124 participants 

 

A new longitudinal study published in PLOS Mental Health reveals that medical cannabis products may significantly improve sleep quality and related symptoms in people with insomnia — especially when standard treatments fail.

 

Over an 18-month period, 124 participants using cannabis-based medicinal products reported sustained improvements in sleep, reduced anxiety or depression, and less pain. Only about 9% experienced mild side effects (fatigue, dry mouth, or worsening insomnia), and no serious adverse events were recorded. 

 

The investigation, led by researchers at Imperial College London, addresses the limitations of many conventional insomnia therapies (dependence, limited efficacy, side effects). Participants were tracked from 1 month up to 18 months of cannabis treatment, assessing changes in self-reported sleep, mood, and quality of life. The positive effects held across the follow-up window, although the authors caution that real-world observational data can’t establish causation or guarantee safety in all populations. 

 

Coauthor Dr Simon Erridge noted that this “real-world evidence” stretches beyond the usual short trials and underscores the need for continued, individualized monitoring and further randomized controlled trials. The research suggests medical cannabis could be an alternative avenue for people with refractory insomnia, supporting its potential role when conventional therapies fail — but stresses that robust clinical trials are needed to determine long-term efficacy, optimal dosing, and safety. 

 

Overall, while the findings are encouraging, they don’t yet justify broad adoption. The study shows promise for cannabis-based treatments in sleep medicine, but also leaves open questions around standardization, long-term risk, and patient selection.

 

 

 

Key Takeaways:

 

1. Sustained sleep gains over 18 months — Insomnia patients using medical cannabis reported long-term improvements in sleep quality, mood, and pain.

 

 

2. Low rate of mild side effects — About 9% reported fatigue, dry mouth, or insomnia worsened; no serious adverse events observed.

 

 

3. Need for stronger evidence — Observational design limits causal claims; randomized controlled trials are needed before mainstream use.

 

 

Adapted From:

 

https://www.sciencedaily.com/releases/2025/09/250901104658.htm

 

Link to case study series:

 

UK Medical Cannabis Registry: A clinical outcomes analysis for insomnia | PLOS Mental Health https://share.google/ybhcADaS80rhYMzFz

 

 

 

 

Competing interests: AA, IC, LE, MV have no conflicts of interest to declare. SE, EC, KM, RC, JJR, MWW, MHS are all either employees or work on as medical practitioners at Curaleaf Clinic. 

 

 

 

 

.. but it stinks.

And gives you foul breath 

On 10/13/2025 at 10:37 AM, roger buttmore said:

.. but it stinks.

Gummies don't. 

7 hours ago, Jingthing said:

Gummies don't. 

 

Good point. True.

13 minutes ago, roger buttmore said:

 

Good point. True.

 

Also 

 

Gel caps

Tincture

 

And basically any food you can think of to eat.